Andrii Bidochko

• Updated: February 13, 2026
• 7 min read

Oura Pushes FDA to Reclassify Wearable Health Features as Low‑Risk Digital Health Screener

Answer: Oura is lobbying the U.S. Food and Drug Administration to create a new “digital health screener” classification that would relax regulatory requirements for low‑risk wearable health features, allowing faster market entry while still ensuring basic safety and accuracy.

Why Oura’s Push Matters Now

In early February 2026, the Finnish‑based Verge reported that Oura Ring’s CEO Tom Hale has taken the fight to Capitol Hill, urging the FDA to carve out a middle ground between the existing “wellness” and “medical device” categories. The proposed “digital health screener” would give innovators a streamlined path to bring features like early‑symptom alerts to consumers without the costly, multi‑year clearance process that currently applies to many moderate‑risk devices.

Background: How the FDA Currently Classifies Wearables

The FDA’s regulatory framework for health technology is built on two broad pillars:

• Wellness devices – products that provide educational or entertainment‑type information (e.g., step counts, basic sleep scores). These are exempt from pre‑market review.
• Medical devices – tools that diagnose, treat, mitigate, or prevent disease. They are assigned a risk class (I‑III) and must undergo varying levels of pre‑market clearance or approval.

Wearables sit in a gray zone because many of them collect clinically relevant data (heart rate variability, oxygen saturation, ECG) but are marketed as “insights” rather than diagnoses. This ambiguity forces companies to either:

1. Invest heavily in FDA clearance, or
2. Label the feature as “wellness,” often diluting its utility to avoid regulatory scrutiny.

The “Wellness” vs. “Medical” Divide

Regulators define wellness features as “intended for general health improvement” and exempt them from the rigorous testing required for medical devices. However, as wearables become more sophisticated—detecting atrial fibrillation, sleep apnea risk, or early signs of infection—the line blurs. The FDA’s 2019 guidance on “mobile medical applications” attempted to clarify the split, but it still leaves many edge cases unresolved.

Oura’s Lobbying Effort and the “Digital Health Screener” Proposal

Tom Hale’s op‑ed in the Wall Street Journal outlined a three‑tiered model:

• Wellness – pure lifestyle data, no health claims.
• Digital health screener – low‑risk features that can alert users to potential health issues but stop short of a diagnosis.
• Medical device – high‑risk, diagnostic or therapeutic tools requiring full FDA clearance.

The “digital health screener” would come with a clear labeling schema, performance thresholds, and a streamlined pre‑market review that focuses on safety and accuracy rather than full clinical validation.

Key Elements of the Proposed Category

• Standardized disclaimer language that the feature is not a diagnosis.
• Mandatory public posting of accuracy metrics (e.g., sensitivity, specificity).
• Fast‑track review timeline (6‑12 months vs. 24‑36 months for full clearance).
• Eligibility limited to devices with a risk profile comparable to a tongue depressor or a pulse oximeter.

Oura’s Rationale

“From the consumer perspective, it should feel the same,” says Dr. Ricky Bloomfield, Oura’s chief medical officer. “We would never expect users to parse FDA categories; they just want reliable, actionable insights.” Bloomfield emphasizes that the new pathway would retain rigorous testing while cutting down on bureaucratic delays that stifle innovation.

“Technology moves faster than the FDA can adapt. A dedicated screener class would give developers a clear, predictable route to market without compromising safety.” – Ricky Bloomfield, Oura CMO

Implications for the Broader Health‑Tech Ecosystem

Adopting a “digital health screener” classification could reshape the market in several ways:

• Accelerated innovation: Start‑ups can iterate faster, bringing new health insights to users within months rather than years.
• Reduced cost barrier: Smaller firms avoid the multi‑million‑dollar expense of full FDA clearance.
• Clearer consumer messaging: Uniform labeling reduces confusion between wellness and medical claims.
• Potential for market saturation: Easier entry may lead to a flood of low‑quality “screener” apps, raising the need for third‑party validation.
• Regulatory precedent: Other agencies (e.g., EU’s MDR) may adopt similar tiered frameworks, harmonizing global standards.

Industry Reaction: Voices from the Frontline

Experts are divided. Some applaud Oura’s pragmatic approach, while others warn that a third classification could muddy the regulatory waters even further.

Supportive Perspectives

Dr. Maya Patel, a digital health researcher at Stanford, notes, “A screener tier acknowledges the reality that many wearables provide clinically useful signals without being full diagnostics. It’s a sensible compromise.”

Cautious Voices

Conversely, FDA policy analyst James Liu cautions, “Adding another category risks creating a ‘gray zone’ where companies may claim a lower risk level to dodge scrutiny, potentially endangering users.”

What This Means for Developers, Start‑ups, and Enterprises

Whether you’re building a niche health app or scaling an enterprise AI platform, the proposed changes could affect your roadmap.

Start‑ups: Faster Time‑to‑Market

Early‑stage companies can leverage the new tier to launch features like early‑symptom alerts without the heavy regulatory lift. For founders looking for a launchpad, UBOS for startups offers a low‑code environment that integrates AI models, data pipelines, and compliance checks in a single workspace.

SMBs: Balancing Cost and Compliance

Small‑ and medium‑size businesses often lack dedicated regulatory teams. UBOS’s solutions for SMBs include pre‑built compliance modules that automatically generate the required accuracy reports for a digital health screener, cutting down on legal overhead.

Enterprises: Scaling with Confidence

Large organizations can embed the new classification into their governance frameworks. The Enterprise AI platform by UBOS provides audit trails, role‑based access, and integration with FDA‑approved data registries, ensuring that even high‑volume deployments stay within regulatory bounds.

Building the Feature Stack

UBOS’s ecosystem makes it easy to assemble the tech stack needed for a digital health screener:

• Web app editor on UBOS – drag‑and‑drop UI for patient dashboards.
• Workflow automation studio – orchestrate data ingestion, model inference, and alert delivery.
• OpenAI ChatGPT integration – natural‑language explanations for screener results.
• Chroma DB integration – vector search for symptom similarity.
• ElevenLabs AI voice integration – audible alerts for hands‑free use.

Real‑World Templates to Accelerate Development

UBOS’s Template Marketplace already hosts several ready‑made solutions that align with the screener concept:

• AI SEO Analyzer – demonstrates how to embed AI‑driven analytics into a web UI.
• AI Article Copywriter – showcases prompt engineering for health‑focused content.
• AI Video Generator – can be repurposed to create educational videos that accompany screener alerts.
• AI Chatbot template – provides a conversational layer for users to ask follow‑up questions about their alerts.
• GPT‑Powered Telegram Bot – enables push notifications directly to a user’s messaging app.

Conclusion: What to Watch in the Coming Months

The FDA has not yet signaled a formal adoption of the “digital health screener” category, but Oura’s lobbying has sparked a broader conversation among regulators, investors, and developers. Key indicators to monitor include:

1. Legislative hearings or public comment periods on wearable regulation.
2. Announcements from other wearable manufacturers (e.g., Whoop, Fitbit) about similar lobbying efforts.
3. Updates to FDA guidance documents that reference “screening” or “low‑risk” health features.
4. Adoption of UBOS’s compliance‑focused templates and tools that align with a potential screener framework.

For tech‑savvy health enthusiasts and professionals, staying ahead of these regulatory shifts can mean the difference between being a market leader or a laggard.

Take Action: Build Your Next Health Feature with UBOS

Ready to prototype a digital health screener without drowning in paperwork? Explore the UBOS homepage for a full suite of AI‑powered tools, check out the UBOS platform overview, and pick a starter template that matches your use case. Need pricing details? The UBOS pricing plans are transparent and scale with your growth.

Join the conversation, share your thoughts on wearable regulation, and let us know which UBOS template you’ll use to bring your next health innovation to market.

Andrii Bidochko

CTO UBOS

Andrii Bidochko is an AI entrepreneur and researcher focused on AI agents, reinforcement learning, and autonomous systems. He writes about the technologies shaping the future of machine intelligence, from frontier models and agent architectures to real-world AI applications.